Insight

The clinical utility of liquid biopsies detecting ctDNA in guiding treatment for patients with mCRC – ESMO

Photo from ESMO/LinkedIn

Jun 28, 2024, 13:15

The clinical utility of liquid biopsies detecting ctDNA in guiding treatment for patients with mCRC – ESMO

ESMO (European Society for Medical Oncology) shared on LinkedIn:

“Data from two presentations at ESMOGI24 highlight the clinical utility of liquid biopsies detecting circulating tumor DNA (ctDNA) in guiding treatment for patients with Metastatic Colorectal Cancer (mCRC) and providing prognostic information post-surgery for patients with stage 3 colon cancer.

To learn more about this topic, read the analysis from Pashtoon Kasi in the latest ESMO Daily Reporter article.”

Source: ESMO/LinkedIn

Agenus cancer ctDNA ESMO ESMO Daily Reporter ESMOGI24 European Society for Medical Oncology Garo Armen Jennifer Buell Liquid Biopsies mCRC Mehraneh Jafari Metastatic colorectal cancer OncoDaily Oncology Pashtoon Kasi Steven O'Day

Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 10

OncoThon 2024 Raises $1.3 Million for Pediatric Cancer Research

Richard Sullivan: Do we need a 'new' Geneva Convention and protocols?

Remembering Virgil Abloh: Louis Vuitton’s Creative Director Honored at 41 After His Brave Battle with Cardiac Angiosarcoma

Special Coverage